Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchs show that cholesterol-lowering drugs cut heart attacks by more than a quarter

12.10.2007
A study into the use of cholesterol-lowering drugs has found they reduce heart attacks by more than 25 per cent.

The 15-year investigation, by researchers from the University of Glasgow, has shown that patients treated with statins for five years suffer 27 per cent fewer non-fatal heart attacks or deaths due to heart disease.

It appears that the statin treatment reduces the rate occurrence of heart disease events, even after patients stop taking the drug.

Professor Ian Ford, who led the study, said: “We believe that this remarkable ongoing benefit is due to a stabilizing of existing disease in the coronary arteries and significant slowing of further progression of disease. This benefit appears to have persisted for 10 years and may have conferred a lifelong advantage on those treated with the statin.”

The results are published in the New England Journal of Medicine.

The investigation was carried out by the same team who produced the landmark 1995 study that opened the door worldwide for patients to be treated with a statin.

The West of Scotland Coronary Prevention Study followed volunteers over a 15-year period to investigate the treatment benefits and assess the long-term safety of statin use.

The first results of the study, published in 1995, showed that the risk of death from coronary heart disease or non-fatal heart attack was reduced significantly in men who were prescribed a statin for five years.

A total of 6595 Scottish middle-aged men, who had high cholesterol levels but who had not previously suffered a heart attack, were used in the study. One half of the group were prescribed a statin, while the others were given a placebo.

These patients have now been followed for 15 years and provided the basis for the latest findings.

Professor Ford said: “The results of the follow-up provide strong support for the safety of five years of statin use.

“When fatal and non-fatal heart disease events were studied, it was found that, despite the fact that most of the participants were not treated with a statin after the first five years of the trial there was evidence of the group originally receiving the statin continuing to be at lower risk of having a heart disease event.

“In fact, remarkably, five years of treatment with a statin resulted in 27 per cent fewer non-fatal heart attacks or deaths due to heart disease over the period of 15 years. There was a significant 12 per cent reduction in deaths over the entire period, with deaths due to heart disease reduced by 22 per cent.

“This suggests that statin treatment has a long-term beneficial effect in slowing the development of coronary artery disease.”

Professor Stuart Cobbe, lead cardiologist in the study, said: “We were very surprised to find that patients who had been treated for 5 years with a statin continued to have significantly fewer heart attacks and other coronary events compared to those treated with a placebo treatment. This benefit appeared to extend at least 10 years after the original trial.

“These results are very reassuring for patients who might be concerned about safety when taking a drug for a very long period of time. There was no evidence of adverse health problems associated with taking a statin for 5 years.

“Importantly, the relative risk reduction in the 10 years after the trial was lower than that observed during the trial, suggesting that there is still additional benefit from continuing to take statin treatment beyond 5 years. The researchers emphasize therefore that this research does not suggest that patients should stop taking their treatment after five years.

Professor Chris Packard, an expert on cholesterol lowering drugs, said: “The impact of statin treatment appeared to persist long after the active phase of the trial. This suggests that the drugs have lasting beneficial effects on the artery wall possibly by stabilising plaques that might be about to rupture and cause a heart attack.

“What is also important to note is that we made use of the electronic records that Scotland has held for hospital admissions, cancer registrations and deaths since the early 1980s. This study, based on following up participants’ electronic medical records, demonstrates the significant benefits that such records can provide for medical researchers. This Scottish resource is unique in the UK and is equalled in very few places worldwide.”

The research was supported by a research grant from the Chief Scientist Office, Scotland.

Martin Shannon | alfa
Further information:
http://www.gla.ac.uk

More articles from Studies and Analyses:

nachricht Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland

nachricht Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

NASA examines Peru's deadly rainfall

24.03.2017 | Earth Sciences

What does congenital Zika syndrome look like?

24.03.2017 | Health and Medicine

Steep rise of the Bernese Alps

24.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>